Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

An Extension Study of CORLUX in the Treatment of Endogenous Cushing`s Syndrome


An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing`s Syndrome




Participants in study C-1073-400 (SEISMIC) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing`s syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator.

Study Status: Active, not recruiting


Condition Intervention Phase
Cushing`s Syndrome Drug: mifepristone Phase 3

Verified by Corcept Therapeutics August, 2012

Sponsored by: Corcept Therapeutics
Information provided by: Corcept Therapeutics identifier: NCT00936741

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism
Cleveland, Ohio 44195
United States

Coleman Gross, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site